Company Focus
Vertex Pharmaceuticals
Latest Vertex Pharmaceuticals News
Pharmaceutical
US biopharma Vertex Pharmaceuticals was trading nearly 2% higher during pre-market trading on Tuesday. This followed Vertex’s presentation of its third-quarter financial results and latest outlook for 2024 as a whole. 5 November 2024
Related News
Insights
Company Spotlight
A biotech start-up aiming to leverage a proprietary lentiviral gene therapy platform designed and developed by GTC specifically for inhaled delivery.
Latest News & Features of interest to Vertex Pharmaceuticals
Biotechnology
UK pharma major AstraZeneca’s Fasenra (benralizumab) recently received Food and Drug Administration (FDA) approval for severe asthma in children aged six to 11, specifically for the eosinophilic phenotype, in over 80 countries, including the USA, European Union, and Japan. 22 May 2024
Biotechnology
Data have been presented from the NOTUS Phase III study on the use of Dupixent (dupilumab) as an add-on maintenance treatment in adults with uncontrolled COPD on maximal standard-of-care inhaled therapy and evidence of type 2 inflammation. 21 May 2024
Biotechnology
US healthcare giant Johnson & Johnson has announced that the Tremfya (guselkumab) QUASAR maintenance study in ulcerative colitis (UC) met its primary endpoint and all major secondary endpoints, including highly statistically significant rates of endoscopic remission. 21 May 2024
Biotechnology
Massachusetts-USA-based biotech-Progentos Therapeutics has announced its launch and the closing of a $65 million Series A round of financing. 21 May 2024
Pharmaceutical
While AstraZeneca’s chief executive Pascal Soriot has been proven right about many of his prior boasts on the company’s future success during his 12-year reign, his latest claim could be questioned even by his strongest supporters. 21 May 2024
Biotechnology
The European Commission (EC) has decided not to adopt the European Medicines Agency’ human medicines committee CHMP's negative opinion of January 24, 2024 on the annual renewal of the conditional marketing authorization of Translarna (ataluren) and has returned the opinion to the CHMP for re-evaluation. 21 May 2024
Biotechnology
Shares of Massachusetts, USA-based muscle specialist Dyne Therapeutics closed up almost 28% at $35.38 yesterday, after it released positive clinical data from its ongoing Phase I/II ACHIEVE trial of DYNE-101. 21 May 2024
Pharmaceutical
Gilead Sciences has announced positive interim results from the ongoing ASSURE study of seladelpar. 20 May 2024
Biotechnology
Swiss family-owned protein specialist Octapharma has appointed pharmaceutical industry veteran Kelly Hearn as vice president of commercial development and marketing of its American company, Octapharma USA.
Ms Hearn will take immediate leadership 20 May 2024
Biotechnology
Inaugurated last Friday (May 17), the Pasteur Fiocruz Center on Immunology and Immunotherapy, located at Fiocruz Ceará, brings together scientists from the France-based Institut Pasteur and Brazil’s Fiocruz, two members of the Pasteur Network, to develop an integrative approach towards immunotherapies applied to both infectious and non-communicable diseases. 20 May 2024
Latest In Brief for Vertex Pharmaceuticals
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Latest Relevant Ones To Watch News
Life science investor Syncona has announced the launch of its newest portfolio company, Slingshot Therapeutics, through the Syncona Accelerator initiative. 14 November 2024
29 October 2024
24 September 2024
19 September 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze